| Date | Time | Source | Announcement |
|---|---|---|---|
| 08 Dec 2016 | 09:44 AM | Holding(s) in Company | |
| 08 Dec 2016 | 09:42 AM | Holding(s) in Company | |
| 08 Dec 2016 | 09:41 AM | Holding(s) in Company | |
| 08 Dec 2016 | 09:39 AM | Holding(s) in Company | |
| 08 Dec 2016 | 09:34 AM | Holding(s) in Company | |
| 08 Dec 2016 | 09:31 AM | Holding(s) in Company | |
| 08 Dec 2016 | 09:29 AM | Holding(s) in Company | |
| 06 Dec 2016 | 07:00 AM | Admission to AIM and First Day of Dealings |
Oxford Biodynamics' international store for clinical smart tests and research kits based on pioneering EpiSwitch® 3D genomic technology.
OBD was spun out of Oxford University in 2007 to commercialize blood tests based on 3D Genomics research. OBD's tests are designed to help people make informed health decisions and reduce healthcare costs.
OBD share price launched at 162p in 2016.